Results 91 to 100 of about 2,176,861 (324)

Position statement : linear prurigo is a subtype of chronic prurigo

open access: yes, 2019
: Background Chronic prurigo (CPG) is a distinct disease characterized by chronic pruritus, history and/or signs of prolonged scratching and multiple pruriginous lesions.
Misery, L.   +34 more
core  

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

open access: yesChronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi   +2 more
wiley   +1 more source

Factors associated with pruritus uremic in chronic kidney failure patients [PDF]

open access: yes, 2020
Objective Uremic pruritus is one of the most distressing symptoms in patients with chronic renal failure. Interestingly, pruritus is not typically found in acute renal failure. Etiology and pathogenesis of uremic pruritus remain unclear.
Harlim, Ago
core   +1 more source

Generalized chronic pruritus with fibromyalgia [PDF]

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2021
Max, Görg   +3 more
openaire   +2 more sources

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

open access: yesEpilepsia, EarlyView.
Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee   +20 more
wiley   +1 more source

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

open access: yesDermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer   +11 more
doaj   +1 more source

Nickel(II) sulphate–induced allergic contact dermatitis as experimental tool to investigate inflammatory pruritus in humans

open access: yesFrontiers in Allergy
Allergic contact dermatitis is a leading cause of occupational skin disease, with nickel(II) sulphate representing one of the most prevalent contact allergies worldwide.
Karoline Lukaschek   +6 more
doaj   +1 more source

Epidemiology of Chronic Kidney Diseases (CKD) in Malaysia and Pakistan, Pathophysiology of CKD-Associated Pruritus and Other CKD-Associated Dermatological Disorders

open access: yesProgress in Microbes and Molecular Biology, 2020
Almost 50–90% of chronic kidney disease patients undergoing haemodialysis have been reported to have Chronic kidney disease-associated pruritus (CKD-aP).
Inayat Ur Rehman, Tahir Mehmood Khan
doaj   +1 more source

PIEZO1 channels in cutaneous free nerve endings: novel insights into itch-scratch-mechanisms

open access: yesSignal Transduction and Targeted Therapy, 2023
Manuel Pedro Pereira   +2 more
doaj   +1 more source

Tofacitinib Regulates β‐Catenin Nuclear Translocation to Inhibit FLS Migration and Alleviate Clinical Symptoms of RA

open access: yesiNew Medicine, EarlyView.
ABSTRACT Objective Tofacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of moderate‐to‐severe rheumatoid arthritis (RA). However, its synovium‐related molecular mechanisms, particularly its regulatory effect on fibroblast‐like synoviocyte (FLS) migration, remain incompletely understood.
Shuqi Fang   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy